Study AER-01-002 uses a novel and precision imaging strategy to enroll 100 mucus plug-high chronic obstructive pulmonary disease (COPD) patients AER-01-002 is well-powered to determine if 28-days of once-daily dosing of fexlamose is safe and improves lung function Fexlamose has been shown in Phase 1 studies of 96 healthy volunteers to be safe, well tolerated and highly differentiated from first generation thiol-based mucolytic drugs.
John Fahy, PhD, is the lead UCSF inventor.